Novo Nordisk As Stock Buy Hold or Sell Recommendation
| NONOF Stock | USD 128.38 2.12 1.68% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Novo Nordisk AS is 'Strong Buy'. Macroaxis provides Novo Nordisk buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NONOF positions. The advice algorithm takes into account all of Novo Nordisk's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Novo Nordisk's buy or sell advice are summarized below:
Real Value 140.11 | Hype Value 126.26 | Market Value 128.38 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Novo Nordisk AS given historical horizon and risk tolerance towards Novo Nordisk. When Macroaxis issues a 'buy' or 'sell' recommendation for Novo Nordisk AS, the advice is generated through an automated system that utilizes algorithms and statistical models.
Novo |
Execute Novo Nordisk Buy or Sell Advice
The Novo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novo Nordisk AS. Macroaxis does not own or have any residual interests in Novo Nordisk AS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novo Nordisk's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Novo Nordisk Trading Alerts and Improvement Suggestions
| The company has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. Novo Nordisk AS has a current ratio of 0.92, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. |
Novo Nordisk Returns Distribution Density
The distribution of Novo Nordisk's historical returns is an attempt to chart the uncertainty of Novo Nordisk's future price movements. The chart of the probability distribution of Novo Nordisk daily returns describes the distribution of returns around its average expected value. We use Novo Nordisk AS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novo Nordisk returns is essential to provide solid investment advice for Novo Nordisk.
| Mean Return | 0.27 | Value At Risk | -2.36 | Potential Upside | 4.11 | Standard Deviation | 2.26 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novo Nordisk historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novo Nordisk Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novo Nordisk or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novo Nordisk's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novo pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.22 | |
β | Beta against NYSE Composite | 0.54 | |
σ | Overall volatility | 2.30 | |
Ir | Information ratio | 0.08 |
Novo Nordisk Volatility Alert
Novo Nordisk AS has relatively low volatility with skewness of 1.48 and kurtosis of 3.23. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novo Nordisk's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novo Nordisk's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novo Nordisk Fundamentals Vs Peers
Comparing Novo Nordisk's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novo Nordisk's direct or indirect competition across all of the common fundamentals between Novo Nordisk and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novo Nordisk or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Novo Nordisk's fundamental indicators could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novo Nordisk to competition |
| Fundamentals | Novo Nordisk | Peer Average |
| Return On Equity | 0.72 | -0.31 |
| Return On Asset | 0.22 | -0.14 |
| Profit Margin | 0.31 % | (1.27) % |
| Operating Margin | 0.43 % | (5.51) % |
| Current Valuation | 292.82 B | 16.62 B |
| Shares Outstanding | 1.72 B | 571.82 M |
| Shares Owned By Institutions | 38.87 % | 39.21 % |
| Price To Earning | 41.24 X | 28.72 X |
| Price To Book | 26.64 X | 9.51 X |
| Price To Sales | 1.73 X | 11.42 X |
| Revenue | 176.95 B | 9.43 B |
| Gross Profit | 148.51 B | 27.38 B |
| EBITDA | 76.8 B | 3.9 B |
| Net Income | 55.52 B | 570.98 M |
| Cash And Equivalents | 31.04 B | 2.7 B |
| Cash Per Share | 13.68 X | 5.01 X |
| Total Debt | 20.77 B | 5.32 B |
| Debt To Equity | 0.34 % | 48.70 % |
| Current Ratio | 0.94 X | 2.16 X |
| Book Value Per Share | 37.10 X | 1.93 K |
| Cash Flow From Operations | 78.89 B | 971.22 M |
| Earnings Per Share | 3.53 X | 3.12 X |
| Price To Earnings To Growth | 1.94 X | 4.89 X |
| Number Of Employees | 54.39 K | 18.84 K |
| Beta | 0.33 | -0.15 |
| Market Capitalization | 318.05 B | 19.03 B |
| Total Asset | 241.26 B | 29.47 B |
| Retained Earnings | 41.06 B | 9.33 B |
| Working Capital | 9.98 B | 1.48 B |
| Current Asset | 51.58 B | 9.34 B |
| Current Liabilities | 41.59 B | 7.9 B |
| Z Score | 9.0 | 8.72 |
| Annual Yield | 0.01 % |
Novo Nordisk Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 2776.21 | |||
| Daily Balance Of Power | 0.5699 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 128.14 | |||
| Day Typical Price | 128.22 | |||
| Price Action Indicator | 1.3 | |||
| Period Momentum Indicator | 2.12 |
About Novo Nordisk Buy or Sell Advice
When is the right time to buy or sell Novo Nordisk AS? Buying financial instruments such as Novo Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Novo Nordisk in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Makers Thematic Idea Now
Chemicals Makers
Companies developing chemicals for crops, soil as well as human, and animals. The Chemicals Makers theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Makers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Novo Nordisk Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |